Latest Pharma and Biotech News
Pharmaceutical
25 November 2024 In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards.
Today's issue
Refine Search
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Biotechnology
A patient in Neurogene’s ongoing Phase I/II trial for Rett syndrome—who was dosed on November 5 with 3E15 vg of NGN-401—has now died from a treatment-related serious adverse event (SAE). 25 November 2024
Generics
Sino-American oncology company BeOne Medicines, until now known as BeiGene, has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Brukinsa (zanubrutinib) in the USA. 25 November 2024
Pharmaceutical
In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards. 25 November 2024
Pharmaceutical
Lexicon Pharmaceuticals has announced a major strategic shift, prioritizing its late-stage pipeline following a rejection by the US Food and Drug Administration (FDA). 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. 25 November 2024
Pharmaceutical
UK pharma major AstraZeneca today released positive high-level results from the CAPItello-281 Phase III trial showing that its Truqap (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT). 25 November 2024
All news
Biotechnology
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
Biotechnology
Swiss ophthalmology specialist Oculis Holding today released positive top-line results from its Phase III OPTIMIZE trial with OCS-01 eye drops. 8 August 2023
Generics
The Indian pharmaceutical industry has made significant progress in reducing its dependency on China for active pharmaceutical ingredients (APIs). 8 August 2023
Pharmaceutical
US clinical-stage drug developer Vistagen saw its shares go into the stratosphere, up as much as 1,272% and closing yesterday on a 677% boost to $13,05, after it released new data on its social anxiety disorder (SAD) candidate that had disappointed in a readout a year ago. 8 August 2023
Pharmaceutical
Shares in Danish diabetes giant Novo Nordisk have risen sharply after positive top-line data were announced from the SELECT cardiovascular outcomes trial. 8 August 2023
Biosimilars
German companies Fresenius Kabi and Formycon have reached a settlement with US healthcare giant Johnson & Johnson for the USA, concerning FYB202, a proposed biosimilar to Stelara (ustekinumab). 8 August 2023
Biotechnology
Shares of Ginkgo Bioworks were down more than 9% at $1.96 in pre-market activity this morning, despite the company announcing a potentially lucrative collaboration. 8 August 2023
Pharmaceutical
UK-based Astex Pharmaceuticals, a pharma company focused on the discovery and development of small molecules for oncology and central nervous system disorders, has expanded its deal with Merck & Co. 8 August 2023
Biotechnology
The dyslipidemia market will be driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of the dyslipidemia population. 8 August 2023
Biotechnology
Nektar Therapeutics’ shares closed up a massive 82.6% at $0.98 yesterday, after it revealed announced that efficacy data previously generated by former partner Eli Lilly for Rezpeg (rezpegaldesleukin) that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly. 8 August 2023
Biotechnology
The recent Life Sciences Competitiveness Indicators published by the UK government suggests that international investors are abandoning the country’s life sciences sector as excessive revenue clawback rates start to bite. 7 August 2023
Biotechnology
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Biotechnology
US cancer drug developer Ikena Oncology today announced the closing of its acquisition of privately-held clinical-stage biotech Pionyr Immunotherapeutics in an all-stock transaction. 7 August 2023
Biotechnology
Increased activity and investment in the development of antibody-drug conjugates (ADCs) has been evident in the oncology market in the past two to three years. 7 August 2023
Biotechnology
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted unanimously by 10 to 0 to recommend routine use of Beyfortus (nirsevimab-alip). 7 August 2023
Biotechnology
Germany’s BioNTech, which shot into the limelight with the development of the first and most successful COVID-19 vaccine, Comirnaty, partnered with Pfizer), today reported financial results for the three months ended June 30, 2023. 7 August 2023
Biotechnology
Shares of UK-based biotech Roquefort Therapeutics were up 9.3% at 8.88 pence by early afternoon, as it announced the successful development of new siRNA sequences and new patent filing for its family of novel anti-cancer siRNA therapeutics. 7 August 2023
Pharmaceutical
An Expert View from Katie Nelson, senior asset manager, and Mairi Dillon, ecosystem manager, at Kadans Science Partner. 7 August 2023
Biotechnology
US pharma major Eli Lilly on Friday announced top-line results from the LIBRETTO-431 study evaluating Retevmo (selpercatinib) versus platinum-based chemotherapy plus pemetrexed – with or without Merck & Co’s Keytruda. 7 August 2023
Pharmaceutical
The US Food and Drug Administration (FDA) approved Japanese drug major Astellas Pharma’s Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) late Friday, 7 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze